Premium Health Management Inc. dba Premium Health
Has Premium Health received an FDA warning letter? Yes. FDA issued a warning letter dated February 20, 2026 concerning products containing semaglutide and tirzepatide.
Letter facts
- Letter date
- February 20, 2026 (2026-02-20)
- Issuing office
- Center for Drug Evaluation and Research (CDER)
- Recipient type
- Telehealth
- Products named
- compounded drug productscompounded semaglutide drug productscompounded tirzepatide drug products
- Violation categories
- Unapproved new drugMisbrandingFalse or misleading claims
Understanding these violation categories
Unapproved new drug
FDA says these products have not been reviewed or approved for safety and effectiveness before being marketed. A warning letter gives the company an opportunity to address the violations.
Misbranding
FDA says the products' labeling, promotion, or directions did not meet federal requirements, such as lacking adequate directions for use or making unsubstantiated claims. A warning letter is FDA's notice of what it believes are significant violations.
False or misleading claims
FDA says the company made claims regarding product equivalence, safety, or FDA approval that were inaccurate or not supported by evidence. A warning letter notifies the recipient to bring promotions into compliance.
Factual Violation Summary
FDA says the website labels suggest Premium Health is the compounder, which it is not, and claims calling the products generic compounded medication imply FDA approval, rendering the products misbranded.
Active Drug Ingredients
Statutory Citations & Specific Allegations
- misbranding under FDCA 502(a)
- misbranding under FDCA 502(bb)
- false or misleading labeling and advertising
- prohibited act under FDCA 301(a)
- unapproved new drugs
More letters about Semaglutide
Recent FDA warning letters concerning Semaglutide:
- RonanRxOctober 30, 2026
- Cheap Medicine ShopSeptember 24, 2026
- Online Generic MedicineSeptember 23, 2026
- Empower PharmacySeptember 18, 2026
- Tex PeptidesAugust 24, 2026
Similar violations (Unapproved new drug)
Recent warning letters with related regulatory findings:
- Cheap Medicine ShopSeptember 24, 2026
- Online Generic MedicineSeptember 23, 2026
- Empower PharmacySeptember 18, 2026
- Tex PeptidesAugust 24, 2026
- Royal Peptides LLCAugust 24, 2026
Regulatory Compliance & Editorial Standard:
The information on this page is compiled strictly from public regulatory enforcement documents published by the U.S. Food and Drug Administration (FDA) and reflects official government records at the time of issuance.
Regulatory Notice: Addressed establishments may have implemented corrective actions or entered into compliance agreements with regulatory authorities. For subsequent remedial filings or official FDA closeout letters, refer directly to the FDA.gov source link above.